Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

Roche Basel Switzerland

Roche trumpets APHINITY data, but did it hit the mark?

Results raise questions about benefit of combining Herceptin with Perjeta

- PMLiVE

AZ’s Lynparza shows PARP inhibitor potential in breast cancer

Findings were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago

Eli Lilly HQ

Lilly adds to data backing breast cancer candidate abemaciclib

US pharma giant’s drug achieves PFS rate of 16.4 months

Rare diseases: meeting the challenge

Problems with regulating orphan drugs

- PMLiVE

FDA panel backs Puma’s breast cancer drug, with reservations

Side effects concerns could see medicines limited

- PMLiVE

Pfizer gets FDA panel recommendation for biosimilar EPO

Product could be the first direct competitor to Epogen and Procrit in the US

Roche Basel Switzerland

Tecentriq bladder cancer approval in doubt after trial failure

The PD-L1 inhibitor failed to extend overall survival in a phase III study

- PMLiVE

When science is not enough

Mundipharma’s Will Dunlop on a new framework to guide development programmes to a better destination

- PMLiVE

Activists torpedo Immunomedics deal with Seattle Genetics

venBio says deal will enrich CEO at shareholders' expense

- PMLiVE

WHO pilots scheme to make biosimilars available to poorer countries

Plans to expand prequalification scheme to medicines such as Roche’s Rituxan and Herceptin

Roche Basel Switzerland

Roche claims another FDA green light for Tecentriq

Wins approval for the treatment's first-line use in bladder cancer

Roche Basel Switzerland

Roche’s Alecensa beats Xalkori as first-line lung cancer therapy

Data shows ALK inhibitor reduces risk of disease worsening

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links